Core Insights - LENSAR, Inc. reported a 48% increase in the installed base of its ALLY Robotic Cataract Laser Systems, reaching approximately 200 systems by the end of 2025, with a backlog of 13 systems pending installation [1][4] - The company achieved recurring revenue of over $46.3 million for the full year, reflecting a 15% increase compared to 2024, with 79% of total revenue derived from recurring sources [1][3][5] - Total revenue for Q4 2025 decreased by approximately $0.7 million, or 4%, compared to Q4 2024, primarily due to a $2.6 million decline in system revenue, although worldwide procedure volume increased by approximately 20% [3][5] Financial Performance - For Q4 2025, total revenue was $16.025 million, down from $16.731 million in Q4 2024, while total revenue for the full year was $58.435 million, up from $53.494 million in 2024 [5][24] - Recurring revenue for Q4 2025 increased by $1.9 million, or 17%, compared to Q4 2024, contributing to a total recurring revenue of $46.306 million for the year [3][5] - The net loss for Q4 2025 was $1.5 million, or ($0.12) per share, significantly reduced from a net loss of $18.7 million, or ($1.61) per share, in Q4 2024 [9][24] Operational Highlights - The company placed 15 ALLY Systems in Q4 2025, contributing to a total installed base of approximately 200 systems, which is a 48% increase from the end of 2024 [4][5] - Worldwide procedure volume for 2025 increased by 22% compared to 2024, indicating robust growth in both U.S. and international markets [2][3] - Selling, general, and administrative expenses rose to $10.3 million in Q4 2025, an increase of 51% from $6.8 million in Q4 2024, primarily due to acquisition-related costs [6][8] Cash and Liabilities - As of December 31, 2025, the company had cash, cash equivalents, and investments totaling $18.0 million, down from $22.5 million at the end of 2024 [11] - Current liabilities increased significantly to $40.574 million as of December 31, 2025, compared to $15.003 million at the end of 2024, largely due to acquisition-related costs [26] Strategic Direction - The company aims to expand its share in the laser-assisted cataract surgery market and enhance the overall robotic laser cataract market, demonstrating confidence in its ALLY System's value [2] - Following the termination of the merger agreement with Alcon, the company retains a merger deposit of $10 million, which will be recorded as other income [12]

Core Viewpoint - LENSAR, Inc. has terminated its merger agreement with Alcon Research, LLC due to anticipated regulatory challenges from the Federal Trade Commission, which has made it unlikely for the merger to receive necessary approvals by the specified deadlines [2][3]. Company Developments - The termination of the merger agreement is viewed as being in the best interest of both companies, allowing LENSAR to retain a $10 million deposit [2]. - LENSAR remains focused on advancing its ALLY Robotic Cataract Laser System™, which has been positioned as a leader in refractive cataract surgery since its commercial launch in 2022 [3]. - The company aims to expand the global installed base and procedure volumes of the ALLY system, emphasizing its commitment to creating long-term value for patients, surgeons, and shareholders [3]. Upcoming Financial Reporting - LENSAR plans to report its fourth quarter and full-year 2025 financial results on March 31, 2026, along with additional details on its strategic direction [4]. - A conference call will be held on the same day at 8:30 a.m. Eastern Time to discuss these results [4]. Product Overview - LENSAR specializes in advanced systems for cataract treatment, with the ALLY Robotic Cataract Laser System™ designed to enhance operational efficiencies and reduce overhead in surgical settings [5]. - The system integrates AI with proprietary imaging and software, aiming to improve surgical outcomes [5].

Core Viewpoint - LENSAR, Inc. is in the process of being acquired by Alcon Research, LLC, with the transaction expected to close in the first half of 2026, pending regulatory approval from the U.S. Federal Trade Commission (FTC) [2]. Company Overview - LENSAR is a commercial-stage medical device company that specializes in advanced systems for cataract treatment and astigmatism management [3]. - The company has developed the ALLY Robotic Cataract Laser System™, which integrates AI and proprietary imaging technology to enhance surgical outcomes and operational efficiency [3]. - The ALLY system is designed for use in sterile operating rooms or in-office surgical suites, aiming to transform premium cataract surgery [3].

Core Insights - LENSAR, Inc. reported a total revenue of $14.3 million for Q3 2025, marking a 6% increase from $13.5 million in Q3 2024, primarily driven by an 11% increase in worldwide procedure volume [3][4] - The installed base of ALLY Robotic Cataract Laser Systems grew by 77% year-over-year, with 185 systems installed as of September 30, 2025 [3][4] - The company is in the process of being acquired by Alcon, with expectations for the transaction to close in Q1 2026 [2][3] Financial Performance - Total revenue for Q3 2025 was $14.3 million, up from $13.5 million in Q3 2024, driven by increased procedure volume [3][4] - Recurring revenue accounted for 75% of total revenue in Q3 2025, compared to 73% in Q3 2024 [4] - The net loss for Q3 2025 was $3.7 million, or ($0.31) per share, compared to a net loss of $1.5 million, or ($0.13) per share, in Q3 2024 [6][18] Operational Highlights - The company placed 18 ALLY Systems in Q3 2025, contributing to a total installed base of approximately 425 laser systems, a 20% increase from the previous year [3][4] - Selling, general, and administrative expenses rose to $12.0 million in Q3 2025, up from $6.1 million in Q3 2024, largely due to acquisition-related costs [5][18] - Research and development expenses increased by 14% to $1.4 million in Q3 2025 compared to $1.2 million in Q3 2024 [5][18] Cash Position - As of September 30, 2025, the company had cash, cash equivalents, and investments totaling $16.9 million, down from $22.5 million at the end of 2024 [8][20] - The cash balance decreased by approximately $3.4 million during Q3 2025 [8]

Core Insights - LENSAR, Inc. reported strong operational performance in Q2 2025, with 18 ALLY Robotic Cataract Laser Systems installed and an additional 18 in backlog, reflecting a 107% growth in the installed base compared to Q2 2024 [1][2] - The company experienced a 23% increase in worldwide procedure volumes compared to the same quarter in the previous year [1][2] - The proposed merger with Alcon has received overwhelming support from shareholders, with over 99% of votes cast in favor, and is expected to close by the end of 2025 [2] Financial Performance - Total revenue for Q2 2025 was $13.9 million, a 10% increase from $12.6 million in Q2 2024, primarily driven by increased procedure volume [3][4] - Recurring revenue accounted for 82% of total revenue in Q2 2025, up from 79% in Q2 2024, with procedure revenue increasing to $8.3 million from $6.9 million year-over-year [4][5] - The net loss for Q2 2025 was $1.8 million, or ($0.15) per share, significantly reduced from a net loss of $9.0 million, or ($0.79) per share, in Q2 2024 [7][20] Operational Highlights - The installed base of ALLY Systems reached approximately 165 units, with a total combined installed base of LENSAR Laser Systems and ALLY Systems increasing to about 410, reflecting a 23% increase year-over-year [3][4] - Selling, general, and administrative expenses rose to $11.7 million in Q2 2025, a 72% increase from $6.8 million in Q2 2024, largely due to acquisition-related costs associated with the merger with Alcon [5][6] - Research and development expenses increased slightly to $1.4 million in Q2 2025 from $1.3 million in Q2 2024 [6] Market Position - LENSAR's laser systems accounted for over 21% of total U.S. cataract procedures in Q2 2025, marking a 3% increase from the previous year [3] - The company continues to focus on advanced robotic laser solutions for cataract treatment, positioning itself as a leader in the medical technology sector [11]

Core Insights - LENSAR, Inc. reported a strong start to 2025 with a 34% increase in revenue and a 33% rise in worldwide procedure volumes compared to the first quarter of 2024 [2][3] - The company placed 14 ALLY Robotic Laser Cataract Systems in the first quarter of 2025, contributing to a total installed base of approximately 150 systems [3][4] - The company is in the process of a proposed merger with Alcon Research, LLC, which has led to increased acquisition-related costs [4][8] Financial Performance - Total revenue for Q1 2025 was $14.2 million, up from $10.6 million in Q1 2024, marking a $3.6 million increase [3][4] - Recurring revenue for the quarter was $11.5 million, representing an 81% recurring revenue percentage, although this is down from 90% in the previous year [4] - The net loss for Q1 2025 was $27.3 million, compared to a net loss of $2.2 million in Q1 2024, primarily due to changes in warrant liability [6][7] Operational Highlights - The company’s laser systems accounted for approximately 22% of total U.S. procedures in Q1 2025 [3] - Selling, general, and administrative expenses increased by 64% to $11.1 million, largely due to acquisition-related costs associated with the Alcon merger [4] - Research and development expenses rose slightly to $1.5 million, a 6% increase from the previous year [5] Cash Position - As of March 31, 2025, LENSAR had cash, cash equivalents, and investments totaling $25.2 million, an increase from $22.5 million at the end of 2024 [8]

Core Insights - LENSAR, Inc. reported significant growth in its financial performance for the fourth quarter and full year of 2024, with total revenue increasing by 38% in Q4 and 27% for the full year compared to 2023 [1][10] - The company placed 31 ALLY Robotic Cataract Laser Systems in Q4 2024, leading to a total of over 80 placements for the year, which contributed to a recurring revenue exceeding $40 million, a 23% increase from 2023 [1][2] - Despite the revenue growth, LENSAR reported a net loss of $18.7 million in Q4 2024, significantly higher than the $3.9 million loss in Q4 2023, primarily due to changes in warrant liabilities linked to stock price appreciation [7][16] Financial Performance - Total revenue for Q4 2024 was $16.7 million, up from $12.1 million in Q4 2023, driven by increased sales of ALLY Systems and higher procedure volumes [3] - For the full year 2024, total revenue reached $53.5 million, compared to $42.2 million in 2023, with procedure volumes in the U.S. increasing by approximately 21% year-over-year [10] - Recurring revenue for the full year exceeded $40 million, with a 23% increase over 2023, indicating a strong growth in the company's service and procedure revenue streams [1][11] Operational Metrics - The total installed base of LENSAR systems increased to approximately 385 by the end of 2024, reflecting a 26% increase from 2023 [1][10] - Worldwide procedure volumes grew by 24% in 2024, with nearly 170,000 procedures performed, marking a significant increase in market activity [2] - The company achieved a market share of over 20% in the U.S. procedure market for the first time, with approximately 75% of U.S. placements being new to LENSAR users [2] Expenses and Losses - Selling, general, and administrative expenses for Q4 2024 were $6.8 million, a 7% increase from $6.4 million in Q4 2023, primarily due to increased marketing expenses to support ALLY growth [4][13] - Research and development expenses decreased to $1.3 million in Q4 2024 from $1.5 million in Q4 2023, reflecting a 9% reduction [5] - The net loss for the full year 2024 was $31.4 million, compared to a net loss of $14.4 million in 2023, largely due to changes in warrant liabilities and an impairment of intangible assets [16] Future Outlook - The company anticipates continued revenue growth in 2025, driven by strong demand for ALLY Systems and regulatory clearances in the EU and Taiwan [18] - Revenue growth in the first quarter of 2025 is expected to align with the 27% growth rate achieved in 2024, with acceleration anticipated in subsequent quarters [18] - LENSAR aims to achieve positive Adjusted EBITDA results in 2025, supported by disciplined capital allocation and projected revenue growth from ALLY placements [18]